PRRG1 Activators
PRRG1 activators encompass a class of small molecules that play a crucial role in modulating the activity of PRRG1, a protein involved in various cellular processes. These activators exert their effects through indirect means, primarily by inhibiting specific signaling pathways that regulate PRRG1 expression. Notably, compounds such as Selumetinib and U0126 are MEK inhibitors that indirectly activate PRRG1 by inhibiting the MAPK/ERK pathway. This inhibition prevents PRRG1 downregulation, fostering sustained PRRG1 activity and influencing cellular processes related to PRRG1 through modulation of the MAPK/ERK signaling cascade.
Other activators, including SB431542, GDC-0941, LY294002, Wortmannin, GSK429286A, and A83-01, exert their effects by suppressing the TGF-β or PI3K/AKT signaling pathways. For instance, SB431542, a TGF-β receptor inhibitor, indirectly activates PRRG1 by suppressing the TGF-β signaling pathway, preventing PRRG1 downregulation, and influencing cellular processes associated with PRRG1 through modulation of TGF-β-mediated signaling.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib, a MEK inhibitor, indirectly activates PRRG1 by inhibiting the MAPK/ERK pathway. This inhibition prevents PRRG1 downregulation, promoting sustained PRRG1 activity. The compound influences cellular processes related to PRRG1 through modulation of the MAPK/ERK signaling cascade. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB431542, a TGF-β receptor inhibitor, indirectly activates PRRG1 by suppressing the TGF-β signaling pathway. This inhibition prevents PRRG1 downregulation, allowing sustained PRRG1 activity and influencing cellular processes associated with PRRG1 through modulation of TGF-β-mediated signaling. | ||||||
GDC-0941 | 957054-30-7 | sc-364498 sc-364498A | 5 mg 10 mg | $188.00 $199.00 | 2 | |
GDC-0941, a PI3K inhibitor, indirectly activates PRRG1 by suppressing the PI3K/AKT pathway. This inhibition prevents PRRG1 downregulation, fostering sustained PRRG1 activity. The compound influences cellular processes related to PRRG1 through modulation of the PI3K/AKT signaling pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly activates PRRG1 by suppressing the PI3K/AKT pathway. This inhibition prevents PRRG1 downregulation, fostering sustained PRRG1 activity. The compound influences cellular processes related to PRRG1 through modulation of the PI3K/AKT signaling pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor, indirectly activates PRRG1 by suppressing the PI3K/AKT pathway. This inhibition prevents PRRG1 downregulation, promoting sustained PRRG1 activity. The compound influences cellular processes related to PRRG1 through modulation of the PI3K/AKT signaling pathway. | ||||||
GSK 429286 | 864082-47-3 | sc-361200 sc-361200B sc-361200A | 1 mg 5 mg 10 mg | $40.00 $125.00 $235.00 | ||
GSK429286A, a TGF-β receptor inhibitor, indirectly activates PRRG1 by suppressing the TGF-β signaling pathway. This inhibition prevents PRRG1 downregulation, allowing sustained PRRG1 activity and influencing cellular processes associated with PRRG1 through modulation of TGF-β-mediated signaling. | ||||||
BMS-754807 | 1001350-96-4 | sc-507396 | 5 mg | $304.00 | ||
BMS-754807, an IGF-1R/IR inhibitor, indirectly activates PRRG1 by suppressing the IGF-1R/IR signaling pathway. This inhibition prevents PRRG1 downregulation, fostering sustained PRRG1 activity. The compound influences cellular processes related to PRRG1 through modulation of the IGF-1R/IR signaling pathway. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363, an AKT inhibitor, indirectly activates PRRG1 by suppressing the PI3K/AKT pathway. This inhibition prevents PRRG1 downregulation, promoting sustained PRRG1 activity. The compound influences cellular processes related to PRRG1 through modulation of the PI3K/AKT signaling pathway. | ||||||
A 83-01 | 909910-43-6 | sc-203791 sc-203791A | 10 mg 50 mg | $202.00 $811.00 | 16 | |
A83-01, a TGF-β receptor inhibitor, indirectly activates PRRG1 by suppressing the TGF-β signaling pathway. This inhibition prevents PRRG1 downregulation, allowing sustained PRRG1 activity and influencing cellular processes associated with PRRG1 through modulation of TGF-β-mediated signaling. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055, a dual mTOR inhibitor, indirectly activates PRRG1 by suppressing mTOR signaling. This inhibition prevents PRRG1 downregulation, promoting sustained PRRG1 activity. The compound influences cellular processes related to PRRG1 through modulation of the mTOR signaling pathway. | ||||||